

Carla LÃ³pez-CausapÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8247856/publications.pdf>

Version: 2024-02-01

46
papers

2,498
citations

331538

21
h-index

214721

47
g-index

57
all docs

57
docs citations

57
times ranked

3552
citing authors

#	ARTICLE	IF	CITATIONS
1	Susceptibility profiles and resistance genomics of <i>Pseudomonas aeruginosa</i> isolates from European ICUs participating in the ASPIRE-ICU trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1862-1872.	1.3	23
2	Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute <i>Pseudomonas aeruginosa</i> infection. <i>Nature Communications</i> , 2021, 12, 2460.	5.8	47
3	Predicting <i>Pseudomonas aeruginosa</i> susceptibility phenotypes from whole genome sequence resistance analysis. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1631-1637.	2.8	36
4	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. <i>Nature</i> , 2021, 595, 707-712.	13.7	363
5	Evaluation of Rapid Polymyxin <i>Pseudomonas</i> test in clinical <i>Pseudomonas aeruginosa</i> isolates with various degrees of multidrug resistance. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab104.	0.9	0
6	Emergence of Resistance to Novel Cephalosporin- β -Lactamase Inhibitor Combinations through the Modification of the <i>Pseudomonas aeruginosa</i> MexCD-OprJ Efflux Pump. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0008921.	1.4	29
7	<i>In Vivo</i> Evolution of GES-2-Lactamases Driven by Ceftazidime/Avibactam Treatment of <i>Pseudomonas aeruginosa</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0098621.	1.4	14
8	Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. <i>Microbiology Spectrum</i> , 2021, 9, e0058521.	1.2	18
9	The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. <i>Nature Genetics</i> , 2021, 53, 1405-1414.	9.4	35
10	A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2677-2699.	1.8	4
11	Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant <i>Pseudomonas aeruginosa</i> isolates in a hollow-fiber infection model. <i>Scientific Reports</i> , 2021, 11, 22178.	1.6	6
12	A Genomic Snapshot of the SARS-CoV-2 Pandemic in the Balearic Islands. <i>Frontiers in Microbiology</i> , 2021, 12, 803827.	1.5	3
13	Emergence of high-level and stable metronidazole resistance in <i>Clostridioides difficile</i> . <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105830.	1.1	4
14	<i>Pseudomonas aeruginosa</i> epidemic high-risk clones and their association with horizontally-acquired β -lactamases: 2020 update. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106196.	1.1	147
15	Temperate Bacteriophages (Prophages) in <i>Pseudomonas aeruginosa</i> Isolates Belonging to the International Cystic Fibrosis Clone (CC274). <i>Frontiers in Microbiology</i> , 2020, 11, 556706.	1.5	18
16	Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> , Including High-Risk Clones, in an <i>In Vitro</i> Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	8
17	Activity of Imipenem-Relebactam against a Large Collection of <i>Pseudomonas aeruginosa</i> Clinical Isolates and Isogenic β -Lactam-Resistant Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	54
18	Association between <i>Pseudomonas aeruginosa</i> O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3217-3220.	1.3	18

#	ARTICLE	IF	CITATIONS
19	Comparative Analysis of Peptidoglycans From <i>Pseudomonas aeruginosa</i> Isolates Recovered From Chronic and Acute Infections. <i>Frontiers in Microbiology</i> , 2019, 10, 1868.	1.5	12
20	Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant <i>Pseudomonas aeruginosa</i> , including high-risk clones. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 18, 37-44.	0.9	16
21	Spanish nationwide survey on <i>Pseudomonas aeruginosa</i> antimicrobial resistance mechanisms and epidemiology. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1825-1835.	1.3	92
22	Profiling the susceptibility of <i>Pseudomonas aeruginosa</i> strains from acute and chronic infections to cell-wall-targeting immune proteins. <i>Scientific Reports</i> , 2019, 9, 3575.	1.6	10
23	Characterization of Hypermutator <i>Pseudomonas aeruginosa</i> Isolates from Patients with Cystic Fibrosis in Australia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	30
24	Emergence of Resistance to Novel Î²-Lactam-Î²-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in <i>Pseudomonas aeruginosa</i> Sequence Type 308. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	10
25	Evolution of the <i>Pseudomonas aeruginosa</i> Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	44
26	Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against <i>Pseudomonas aeruginosa</i> Sequence Type 175 in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	21
27	Susceptibility to R-pyocins of <i>Pseudomonas aeruginosa</i> clinical isolates from cystic fibrosis patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2770-2776.	1.3	19
28	The Versatile Mutational Resistome of <i>Pseudomonas aeruginosa</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 685.	1.5	181
29	Ceftolozane/tazobactam for the treatment of multidrug resistant <i>Pseudomonas aeruginosa</i> : experience from the Balearic Islands. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2191-2200.	1.3	53
30	Insights into the evolution of the mutational resistome of <i>Pseudomonas aeruginosa</i> in cystic fibrosis. <i>Future Microbiology</i> , 2017, 12, 1445-1448.	1.0	8
31	Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the <i>Caenorhabditis elegans</i> <i>Pseudomonas aeruginosa</i> Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	39
32	Genomics and Susceptibility Profiles of Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Isolates from Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	108
33	Antibiotic resistance and population structure of cystic fibrosis <i>Pseudomonas aeruginosa</i> isolates from a Spanish multi-centre study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 334-341.	1.1	20
34	Evolution of the <i>Pseudomonas aeruginosa</i> mutational resistome in an international Cystic Fibrosis clone. <i>Scientific Reports</i> , 2017, 7, 5555.	1.6	117
35	Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating <i>Pseudomonas aeruginosa</i> Chronic Respiratory Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2912-2922.	1.4	25
36	Surfactant Protein A Recognizes Outer Membrane Protein OprH on <i>Pseudomonas aeruginosa</i> Isolates From Individuals With Chronic Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1449-1455.	1.9	17

#	ARTICLE	IF	CITATIONS
37	Deciphering the Resistome of the Widespread <i>Pseudomonas aeruginosa</i> Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7415-7423.	1.4	99
38	Nosocomial dissemination of VIM-2-producing ST235 <i>Pseudomonas aeruginosa</i> in Lithuania. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 195-200.	1.3	21
39	Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations. <i>PLoS ONE</i> , 2015, 10, e0135199.	1.1	62
40	The problems of antibiotic resistance in cystic fibrosis and solutions. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 73-88.	1.0	49
41	The increasing threat of <i>Pseudomonas aeruginosa</i> high-risk clones. <i>Drug Resistance Updates</i> , 2015, 21-22, 41-59.	6.5	475
42	El virus respiratorio sincitial como causante de infecciones respiratorias agudas en el adulto. ¿Una enfermedad emergente?. <i>Revista Clinica Espanola</i> , 2015, 215, 418-419.	0.2	9
43	Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices. <i>BMC Microbiology</i> , 2014, 14, 335.	1.3	8
44	Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in <i>Pseudomonas aeruginosa</i> Cystic Fibrosis Chronic Lung Infection. <i>PLoS ONE</i> , 2013, 8, e71001.	1.1	69
45	<i>In Vivo</i> Selection of Moxifloxacin-Resistant <i>Clostridium difficile</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2788-2789.	1.4	4
46	Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Microbiology Spectrum</i> , 0, , .	1.2	1